Cargando…
P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032
Autores principales: | Iyer, Swaminathan, Jagadeesh, Deepa, Domingo Domènech, Eva, Benedetti, Fabio, Rodriguez Izquierdo, Antonia, Bouabdallah, Kamal, Vitolo, Umberto, Illidge, Tim, Liu, Jingmin, Knowles, Scott, Horwitz, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430937/ http://dx.doi.org/10.1097/01.HS9.0000971416.40088.99 |
Ejemplares similares
-
Role of stem cell transplant in CD30(+) PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
por: Savage, Kerry J., et al.
Publicado: (2022) -
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
por: Cranmer, Holly, et al.
Publicado: (2022) -
PB2125: LYMPHOMATOID PAPULOSIS-LIKE (LYP-LIKE) AFTER BRENTUXIMAB VEDOTIN-CHP (BV-CHP) TREATMENT FOR ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
por: Lopez Pereira, P., et al.
Publicado: (2022) -
A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy
por: Mallipudi, Rajiv M., et al.
Publicado: (2019) -
Antimicrobial activity of chicken and turkey heterophil peptides CHP1, CHP2, THP1, and THP3
por: Evans, Ellen W., et al.
Publicado: (1995)